Incyte Stock Analysis

INCY -  USA Stock  

USD 83.96  0.83  1.00%

The current indifference towards the small price fluctuations of Incyte Corp may raise some interest from investors. The stock closed today at a share price of 83.96 on 2,074,200 in trading volume. The company executives did not add any value to Incyte Corp investors in May. However, most investors can still diversify their portfolios with Incyte Corp to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.59. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Please see Risk vs Return Analysis.

Search Stock Analysis 

 
Refresh
The Incyte Corp stock analysis report makes it easy to digest most publicly released information about Incyte Corp and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Incyte stock analysis module also helps to analyze the Incyte Corp price relationship with some important fundamental indicators such as market cap and management efficiency.

Incyte Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.36. Incyte Corp recorded a loss per share of 1.36. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 1st of September 2000. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1773 people. To learn more about Incyte Corp call Herve Hoppenot at 302 498-6700 or check out www.incyte.com.

Incyte Corp Quarterly Cost of Revenue

29.22 MillionShare

Incyte Corp Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Incyte Corp's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Incyte Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Incyte Corp was previously known as Incyte Corp and was traded on NASDAQ Exchange under the symbol ICY.
The company reported the previous year's revenue of 2.67 B. Net Loss for the year was (295.7 M) with profit before overhead, payroll, taxes, and interest of 276.63 M.
Incyte Corp currently holds about 1.8 B in cash with (124.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.19.
Incyte Corp has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: Incyte Corp. gains 0.4350 percent for June 16 - Equities.com

Incyte Corp Upcoming and Recent Events

Earnings reports are used by Incyte Corp to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Incyte Corp previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End8th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Incyte Largest EPS Surprises

Earnings surprises can significantly impact Incyte Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-04-30
2015-03-31-0.1-0.11-0.0110 
1998-07-14
1998-06-300.090.10.0111 
1997-04-17
1997-03-310.030.02-0.0133 
View All Earnings Estimates

Incyte Corp SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Incyte Corp prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Incyte Corp investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Incyte Corp specific information freely available to individual and institutional investors to make a timely investment decision.
27th of May 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
18th of May 2021
Unclassified Corporate Event
View
4th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
19th of February 2021
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
16th of February 2021
Unclassified Corporate Event
View
11th of February 2021
Unclassified Corporate Event
View
10th of February 2021
Unclassified Corporate Event
View
9th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Incyte Corp Thematic Classifications

In addition to having Incyte Corp stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Incyte Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Incyte Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Incyte Corp backward and forwards among themselves. Incyte Corp's institutional investor refers to the entity that pools money to purchase Incyte Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Baker Bros Advisors LpCommon Shares32 M2.6 B
Price T Rowe Associates IncCommon Shares30.1 M2.4 B
Vanguard Group IncCommon Shares20.4 M1.7 B
Blackrock IncCommon Shares17.7 M1.4 B
Wellington Management Group LlpCommon Shares12.9 M1.1 B
State Street CorpCommon Shares8.4 M678.7 M
Capital International InvestorsCommon Shares5.5 M447.2 M
Note, although Incyte Corp's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Incyte Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 18.28 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte Corp's market, we take the total number of its shares issued and multiply it by Incyte Corp's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Incyte Profitablity

Incyte Corp's profitability indicators refer to fundamental financial ratios that showcase Incyte Corp's ability to generate income relative to its revenue or operating costs. If, let's say, Incyte Corp is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Incyte Corp's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Incyte Corp's profitability requires more research than a typical breakdown of Incyte Corp's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (11.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.07.
Last ReportedProjected for 2021
Return on Investment(8.34) (9.00) 
Return on Average Assets(0.09) (0.1) 
Return on Average Equity(0.13) (0.13) 
Return on Invested Capital(0.23) (0.24) 
Return on Sales(0.09) (0.09) 

Management Efficiency

The entity has return on total asset (ROA) of (4.32) % which means that it has lost $4.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (11.35) %, meaning that it created substantial loss on money invested by shareholders. Incyte Corp management efficiency ratios could be used to measure how well incyte corp manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -9 in 2021. Return on Average Assets is likely to drop to -0.1 in 2021. Incyte Corp Total Assets are fairly stable at the moment as compared to the past year. Incyte Corp reported Total Assets of 3.56 Billion in 2020. Assets Non Current is likely to rise to about 1.3 B in 2021, whereas Current Assets are likely to drop slightly above 1.9 B in 2021.
Last ReportedProjected for 2021
Book Value per Share 11.97  12.92 
Enterprise Value over EBIT(76.00) (82.00) 
Enterprise Value over EBITDA(98.71) (101.31) 
Price to Book Value 7.29  7.87 
Tangible Assets Book Value per Share 14.82  11.98 
Enterprise Value17.6 B16.2 B
Tangible Asset Value3.2 B3.5 B

Technical Drivers

As of the 19th of June, Incyte Corp retains the Market Risk Adjusted Performance of 0.2418, risk adjusted performance of 0.0318, and Downside Deviation of 1.95. Incyte Corp technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Incyte Corp, which can be compared to its competitors. Please check out Incyte Corp market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Incyte Corp is priced fairly, providing market reflects its last-minute price of 83.96 per share. Given that Incyte Corp has jensen alpha of 0.0472, we strongly advise you to confirm Incyte Corp's regular market performance to make sure the company can sustain itself at a future point.

Incyte Corp Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Incyte Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Incyte Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dashyant Dhanak few days ago via Macroaxis 
Exercise or conversion by Dashyant Dhanak of 3845 shares of Incyte Corp subject to Rule 16b-3
Dashyant Dhanak over two weeks ago via Macroaxis 
Sale by Dashyant Dhanak of 5 shares of Incyte Corp
High Katherine A over two weeks ago via Macroaxis 
Acquisition by High Katherine A of 8010 shares of Incyte Corp subject to Rule 16b-3
Bienaime Jean Jacques over three weeks ago via Macroaxis 
Acquisition by Bienaime Jean Jacques of 1923 shares of Incyte Corp subject to Rule 16b-3
Baker Bros Advisors Lp over a month ago via Macroaxis 
Exercise or conversion by Baker Bros Advisors Lp of 20000 shares of Incyte Corp subject to Rule 16b-3
Dashyant Dhanak over a month ago via Macroaxis 
Sale by Dashyant Dhanak of 6 shares of Incyte Corp
Maria Pasquale over a month ago via Macroaxis 
Exercise or conversion by Maria Pasquale of 127 shares of Incyte Corp subject to Rule 16b-3
Maria Pasquale over two months ago via Macroaxis 
Payment of 517 shares by Maria Pasquale of Incyte Corp subject to Rule 16b-3
Dashyant Dhanak over two months ago via Macroaxis 
Sale by Dashyant Dhanak of 6 shares of Incyte Corp
Paul Clancy over two months ago via Macroaxis 
Acquisition by Paul Clancy of 298 shares of Incyte Corp subject to Rule 16b-3
Morrissey Michael James over two months ago via Macroaxis 
Sale by Morrissey Michael James of 20000 shares of Incyte Corp
Maria Pasquale over three months ago via Macroaxis 
Exercise or conversion by Maria Pasquale of 128 shares of Incyte Corp subject to Rule 16b-3

Incyte Corp Predictive Daily Indicators

Incyte Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Incyte Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Incyte Corp Forecast Models

Incyte Corp time-series forecasting models is one of many Incyte Corp's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Incyte Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Incyte Corp Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Incyte Corp stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Incyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Incyte Corp. By using and applying Incyte Stock analysis, traders can create a robust methodology for identifying Incyte entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(8.28) (8.50) 
EBITDA Margin(0.07) (0.07) 
Gross Margin 0.95  0.91 
Profit Margin(0.11) (0.12) 
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1773 people.

Current Incyte Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Incyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Incyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
97.1Hold10Odds
Incyte Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Incyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Incyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Incyte Corp, talking to its executives and customers, or listening to Incyte conference calls.
Incyte Analyst Advice Details

Incyte Stock Analysis Indicators

Incyte Corp stock analysis indicators help investors evaluate how Incyte Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Incyte Corp shares will generate the highest return on investment. By understating and applying Incyte Corp stock analysis, traders can identify Incyte Corp position entry and exit signals to maximize returns.
Quick Ratio3.62
Fifty Two Week Low75.52
Revenue Growth36.30%
Average Daily Volume Last 10 Day1.37M
Shares Short Prior Month5.57M
Average Daily Volume In Three Month1.18M
Earnings Growth35.40%
Shares Percent Shares Out2.25%
Earnings Quarterly Growth35.00%
Gross Margins10.37%
Forward Price Earnings18.68
Short Percent Of Float3.21%
Float Shares185.97M
Fifty Two Week High110.37
Fifty Day Average83.33
Enterprise Value To Ebitda-85.71
Two Hundred Day Average84.49
Enterprise Value To Revenue6.03
Please see Risk vs Return Analysis. Note that the Incyte Corp information on this page should be used as a complementary analysis to other Incyte Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Incyte Corp Stock analysis

When running Incyte Corp price analysis, check to measure Incyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte Corp is operating at the current time. Most of Incyte Corp's value examination focuses on studying past and present price action to predict the probability of Incyte Corp's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Incyte Corp's price. Additionally, you may evaluate how the addition of Incyte Corp to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
The market value of Incyte Corp is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte Corp's value that differs from its market value or its book value, called intrinsic value, which is Incyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte Corp's market value can be influenced by many factors that don't directly affect Incyte Corp underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine Incyte Corp value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.